SloveniaSlovenia

EIB loan: BIA Separations expands

29.04.2009

Ljubljana – BIA Separations d.o.o., the Slovenian specialist for downstream processing of biologicals using monoliths, has received an EUR8m cash injection from the European Investment Bank (EIB). EIB president Philippe Maystadt and Dr. Aleš Štrancar, the company’s CEO, signed the loan agreement, making BIA the first European SME to receive a loan under the Risk Sharing Finance Facility (RSFF) scheme, a joint venture between the European Commission and EIB intended to improve access to debt financing for private companies. “We will put the money into the development of our new purification technologies for the biopharmaceutical industries and expand into a new 3000 m2 R&D and production facility,” BIA’s international marketing manager Gregor Krajnc told EuroBiotechNews. BIA’s methacrylate polymers can be used in short chromatographic resins and offer an improved separation capa­city for large biological molecules such as pegylated proteins and antibodies compared to conventional chromatographic media. While production capacities for biologicals has expanded partly up to the 10g/l range, downstream processing has increasingly become a bottleneck in production processes. Conventional sepa­ration techniques suffer from limited mass transfer.

New biotech center

Additionally, the company laid the cornerstone for a new facility located in Ajdovšcina. With this expansion of its production capacity 50 kilometres west of the Slovenian capital Ljubljana, BIA Separations is moving into a high-technology oriented region where it will, in conjunction with University of Nova Gorica, establish a biotech incubator for the region. One of the roles the incubator will play is to help in the establisment of a biotechnology programme at the nearby university, thereby creating a pool of highly educated personnel for BIA Separations and other companies moving into the region, and meeting long-term human resources.

SloveniaSlovenia

12.08.2005

Zagreb - Croatia's Government passed a new law on genetically modified organisms (GMO), which replaces the “biotechnology-regulating provisions” of the Law on the Protection of Nature that up to now regulated the importation,...

SloveniaSlovenia

10.07.2005

Ljubljana - Slovenian pharma company Pharmaswiss and Swiss pharma group Helsinn Healthcare SA have signed a licensing agreement granting Pharma-swiss the exclusive license and distribution rights for ALOXI®, a strong and...

SloveniaSlovenia

10.07.2005

Brac - The “Fall 2005 Course on Bioprocess Engineering”, organized by the EFB's Working Group on Bioreactor Performance in collaboration with the European Section on Biochemical Engineering Science, will be held from September...

SloveniaSlovenia

05.02.2005

Zagreb - The 4th International Conference on “Biotechnology and Immunomodulatory Drugs” will open its gates from February 20-23, 2005, in Zagreb, Croatia. Organized amongst others by the Croatian Society of Biotechnology and...

SloveniaSlovenia

09.10.2004

Ljubljana - Slovenia's supreme court has rejected an appeal by US-drug group Merck & Co. Inc. in August, ending a 10-year patent dispute with local drug maker Krka d.d. over one of its best-selling drug. The court rejected a...

SloveniaSlovenia

06.08.2004

Opatija - Nutrition-related biotechnology has been subject to many controverse public debates lately. The organizers of the “2nd Central European Meeting - 5th Croatian Congress of Food Technologists, Biotechnologists und...

SloveniaSlovenia

09.04.2004

Ljubljana - BIA Separations, specialized in the short monolithic column technology, will hold the “First Summer School on Monoliths for Biochro-matography, Bioconversion, and So-lid Phase Synthesis” in Potoroz, Slo-venia, from...

SloveniaSlovenia

05.03.2004

Menges - Lek Pharmaceuticals inaugurated a new manufacturing plant (PORT1) for the production of biopharmaceuticals - such as human proteins for therapeutic applications - near the Slovenian capital Lubljana in Menges in early...

SloveniaSlovenia

05.02.2004

Ljubljana - Slovenian pharmaceutical company Lek d.d. successfully defended in late December its patent EP 1 095 037, which covers Lek's synthesis of Ome-prazole before the Board of Appeal of the European Patent Office....

SloveniaSlovenia

23.11.2003

Ljubljana - Scientists at the Department of Biochemistry and Molecular Biology, Jozef Stefan Institute, Ljubljana, have identified an intracellular membrane receptor for a snake venom secretory phospholipase A (sPLA). The...

Displaying results 11 to 20 out of 22

< Previous 11-20 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/nc/news/messages-archive/archive-slovenia/browse/1/article/eib-loan-bia-separations-expands.html

Image Gallery

Stock list

All quotes

TOP

  • GW PHARMACEUTICALS (UK)305.50 GBP39.3%
  • NEWRON (CH)15.60 CHF20.0%
  • TOPOTARGET (DK)3.52 DKK16.9%

FLOP

  • XENETIC BIOSCIENCES (UK)6.00 GBP-14.3%
  • WILEX (D)0.84 EUR-8.7%
  • GENFIT (F)22.42 EUR-8.1%

TOP

  • BIOTECH PHARMACON (N)18.80 NOK70.9%
  • WILEX (D)0.84 EUR47.4%
  • E-THERAPEUTICS (UK)27.75 GBP38.8%

FLOP

  • CYTOS (CH)0.17 CHF-93.8%
  • BIONOR PHARMA (N)2.11 NOK-47.1%
  • IMMUNICUM AB (S)16.60 SEK-38.1%

TOP

  • SILENCE THERAPEUTICS (UK)261.00 GBP6265.9%
  • IXICO (UK)68.00 GBP750.0%
  • PHARMING (NL)0.50 EUR733.3%

FLOP

  • CYTOS (CH)0.17 CHF-96.0%
  • EVOCUTIS (UK)0.22 GBP-92.3%
  • AGENNIX (D)0.04 EUR-80.0%

No liability assumed, Date: 22.04.2014

Current issue

All issues

Product of the week

Products

Events

All Events

Partner-Events

München

BioVaria 2014

Frankfurt am Main

7th DVFA Life Science Conference

White Paper